- In January 2022, Novartis AG's collaboration with Alnylam to investigate targeted therapy for liver function restoration holds promise for the bromhidrosis disease treatment market. Given the liver's role in metabolizing odorous compounds, advancements in liver function restoration may indirectly impact bromhidrosis treatment
- In February 2022, Ipsen Pharma's exclusive negotiations with Mayoly Spindler for its consumer healthcare business may influence the market by potentially introducing new treatments or products targeting bromhidrosis. This move could diversify treatment options and lead to innovative solutions for managing the condition
- In May 2022, Pfizer Inc.'s acquisition of Biohaven Pharmaceutical Holding Company Ltd. for CGRP receptor antagonists' commercialization outside the U.S. might have implications for bromhidrosis treatment. CGRP antagonists are being explored for various conditions, including neurological and dermatological disorders, suggesting potential avenues for addressing bromhidrosis symptoms
